Canthaxanthin ameliorates atopic dermatitis in mice by suppressing Th2 immune response
Authors:
- 8 January 2025
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 147, 113975
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82271782)
- National Natural Science Foundation of China (82471852)
- Southern Medical University (YZ2023ZX04)
This publication has 38 references indexed in Scilit:
- Secoisolariciresinol diglucoside-derived metabolite, enterolactone, attenuates atopic dermatitis by suppressing Th2 immune responseInternational Immunopharmacology, 2022
- Canthaxanthin shows anti-liver aging and anti-liver fibrosis effects by down-regulating inflammation and oxidative stress in vivo and in vitroInternational Immunopharmacology, 2022
- Update on the Pathogenesis and Therapy of Atopic DermatitisClinical Reviews in Allergy & Immunology, 2021
- The Role of the Microbiome and Microbiome-Derived Metabolites in Atopic Dermatitis and Non-Histaminergic ItchAmerican Journal of Clinical Dermatology, 2020
- 2′-fucosyllactose inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response via the STAT3 signaling pathwayInternational Immunopharmacology, 2020
- Assessing the current treatment of atopic dermatitis: Unmet needsJournal of Allergy and Clinical Immunology, 2017
- Canthaxanthin: From molecule to functionMolecular Nutrition & Food Research, 2016
- Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrateJournal of the American Academy of Dermatology, 2015
- The Role of Short-Chain Fatty Acids in Health and Disease2014
- Mast cells in atopic dermatitisCurrent Opinion in Immunology, 2009